{"success":true,"data":{"pressRelease":{"id":"145593","rtpr_id":"nBw6mQgXsa-20260916","ticker":"GOSS","exchange":"NASDAQ","all_tickers":["GOSS"],"title":"Gossamer Bio Appoints Greg Ciongoli to Board of Directors","author":"Business Wire","published_at":"2026-09-16T20:01:00.082Z","article_body":"Gossamer Bio Appoints Greg Ciongoli to Board of Directors\n\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company\nfocused on the development and commercialization of seralutinib for the\ntreatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension\nassociated with interstitial lung disease (PH-ILD), today announced that Greg\nCiongoli has been appointed to the Company's Board of Directors, effective\nSeptember 16, 2026. Mr. Ciongoli will also serve as a member of the Audit\nCommittee.\n\nMr. Ciongoli has served as the Founder and Managing Partner of Adiumentum\nCapital Management, a Boston-based investment firm, since April 2024. Prior to\nAdiumentum, he was a Partner at the Baupost Group, where he worked on a broad\nrange of public and private equity investments. Mr. Ciongoli also serves on\nthe boards of directors of REGENXBIO Inc., Zymeworks, Inc. and Atara\nBiotherapeutics, Inc. He is actively involved in a number of local\nnot-for-profit organizations. Mr. Ciongoli graduated from Princeton University\nwith an A.B. and received his M.B.A. from Harvard Business School.\n\n“We are pleased to welcome Greg to our Board,” said Faheem Hasnain,\nChairman, Co-Founder and Chief Executive Officer of Gossamer Bio. “His deep\ninvestment experience and perspective on value creation will be an asset as we\nadvance seralutinib toward a potential FDA approval and work to bring a new\ntreatment option to patients with pulmonary hypertension.”\n\n“I am excited to join the Gossamer Bio Board at such an important time for\nthe Company,” said Mr. Ciongoli. “Seralutinib represents a compelling\nopportunity to address a serious unmet need, and I look forward to supporting\nthe team as it advances the program.”\n\nAbout Gossamer Bio\n\nGossamer Bio is a biopharmaceutical company focused on the development and\ncommercialization of seralutinib for the treatment of pulmonary arterial\nhypertension and pulmonary hypertension associated with interstitial lung\ndisease. Its goal is to be an industry leader in, and to enhance the lives of\npatients living with, pulmonary hypertension.\n\nForward-Looking Statements\n\nGossamer cautions you that statements contained in this press release\nregarding matters that are not historical facts are forward-looking\nstatements. These statements are based on the Company's current beliefs and\nexpectations. Such statements include, but are not limited to, statements\nregarding advancing seralutinib toward a potential FDA approval and working to\nbring a new treatment option to patients with pulmonary hypertension. The\ninclusion of forward-looking statements should not be regarded as a\nrepresentation by Gossamer that any of its plans will be achieved. Actual\nresults may differ from those set forth in this press release due to the risks\nand uncertainties inherent in Gossamer's business, and other risks described\nin the Company's prior press releases and the Company's filings with the\nSecurities and Exchange Commission (SEC), including under the heading “Risk\nFactors” in the Company's annual report on Form 10-K and any subsequent\nfilings with the SEC. You are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof, and\nGossamer undertakes no obligation to update such statements. All\nforward-looking statements are qualified in their entirety by this cautionary\nstatement, which is made under the safe harbor provisions of the Private\nSecurities Litigation Reform Act of 1995.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260916187751/en/\n(https://www.businesswire.com/news/home/20260916187751/en/)\n\nFor Investors and Media: \n\nBryan Giraudo, Chief Financial Officer & Chief Operating Officer\n\nGossamer Bio Investor Relations\n\nir@gossamerbio.com (mailto:ir@gossamerbio.com)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw6mQgXsa-20260916","title":"Gossamer Bio Appoints Greg Ciongoli to Board of Directors","author":"Business Wire","ticker":"GOSS","created":"2026-09-16T20:01:00.082Z","tickers":["GOSS"],"exchange":"NASDAQ","article_body":"Gossamer Bio Appoints Greg Ciongoli to Board of Directors\n\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company\nfocused on the development and commercialization of seralutinib for the\ntreatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension\nassociated with interstitial lung disease (PH-ILD), today announced that Greg\nCiongoli has been appointed to the Company's Board of Directors, effective\nSeptember 16, 2026. Mr. Ciongoli will also serve as a member of the Audit\nCommittee.\n\nMr. Ciongoli has served as the Founder and Managing Partner of Adiumentum\nCapital Management, a Boston-based investment firm, since April 2024. Prior to\nAdiumentum, he was a Partner at the Baupost Group, where he worked on a broad\nrange of public and private equity investments. Mr. Ciongoli also serves on\nthe boards of directors of REGENXBIO Inc., Zymeworks, Inc. and Atara\nBiotherapeutics, Inc. He is actively involved in a number of local\nnot-for-profit organizations. Mr. Ciongoli graduated from Princeton University\nwith an A.B. and received his M.B.A. from Harvard Business School.\n\n“We are pleased to welcome Greg to our Board,” said Faheem Hasnain,\nChairman, Co-Founder and Chief Executive Officer of Gossamer Bio. “His deep\ninvestment experience and perspective on value creation will be an asset as we\nadvance seralutinib toward a potential FDA approval and work to bring a new\ntreatment option to patients with pulmonary hypertension.”\n\n“I am excited to join the Gossamer Bio Board at such an important time for\nthe Company,” said Mr. Ciongoli. “Seralutinib represents a compelling\nopportunity to address a serious unmet need, and I look forward to supporting\nthe team as it advances the program.”\n\nAbout Gossamer Bio\n\nGossamer Bio is a biopharmaceutical company focused on the development and\ncommercialization of seralutinib for the treatment of pulmonary arterial\nhypertension and pulmonary hypertension associated with interstitial lung\ndisease. Its goal is to be an industry leader in, and to enhance the lives of\npatients living with, pulmonary hypertension.\n\nForward-Looking Statements\n\nGossamer cautions you that statements contained in this press release\nregarding matters that are not historical facts are forward-looking\nstatements. These statements are based on the Company's current beliefs and\nexpectations. Such statements include, but are not limited to, statements\nregarding advancing seralutinib toward a potential FDA approval and working to\nbring a new treatment option to patients with pulmonary hypertension. The\ninclusion of forward-looking statements should not be regarded as a\nrepresentation by Gossamer that any of its plans will be achieved. Actual\nresults may differ from those set forth in this press release due to the risks\nand uncertainties inherent in Gossamer's business, and other risks described\nin the Company's prior press releases and the Company's filings with the\nSecurities and Exchange Commission (SEC), including under the heading “Risk\nFactors” in the Company's annual report on Form 10-K and any subsequent\nfilings with the SEC. You are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof, and\nGossamer undertakes no obligation to update such statements. All\nforward-looking statements are qualified in their entirety by this cautionary\nstatement, which is made under the safe harbor provisions of the Private\nSecurities Litigation Reform Act of 1995.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260916187751/en/\n(https://www.businesswire.com/news/home/20260916187751/en/)\n\nFor Investors and Media: \n\nBryan Giraudo, Chief Financial Officer & Chief Operating Officer\n\nGossamer Bio Investor Relations\n\nir@gossamerbio.com (mailto:ir@gossamerbio.com)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-16T20:01:00.117527183Z","server_sent_at_ms":1789588860117},"received_at":"2026-09-16T20:01:00.175Z","source_url":"https://www.businesswire.com/news/home/20260916187751/en/"},"analysis":{"id":"134427","press_release_id":"145593","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Gossamer Bio appointed Greg Ciongoli to its Board of Directors, effective September 16, 2026, with a seat on the Audit Committee.\n\nCiongoli is founder and managing partner of Boston-based Adiumentum Capital Management and previously a partner at the Baupost Group; he also sits on the boards of REGENXBIO, Zymeworks, and Atara Biotherapeutics.\n\nCEO Faheem Hasnain framed the addition as bringing investment and value-creation perspective as Gossamer advances seralutinib toward a potential FDA approval in pulmonary arterial hypertension and PH-ILD.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Value-investor with audit committee role joins GOSS board as seralutinib heads toward a potential FDA approval."},"keyFigures":{},"quotedText":"investment experience and perspective on value creation will be an asset","namedEntities":{"people":[{"name":"Greg Ciongoli","role":"Newly appointed Director and Audit Committee member, Gossamer Bio"},{"name":"Faheem Hasnain","role":"Chairman, Co-Founder and CEO, Gossamer Bio"},{"name":"Bryan Giraudo","role":"CFO & COO, Gossamer Bio (investor/media contact)"}],"products":["seralutinib"],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS","relationship":"filer"},{"name":"Adiumentum Capital Management","relationship":"new director's current firm (founder & managing partner)"},{"name":"Baupost Group","relationship":"new director's prior employer (partner)"},{"name":"REGENXBIO Inc.","relationship":"other board seat held by new director"},{"name":"Zymeworks, Inc.","relationship":"other board seat held by new director"},{"name":"Atara Biotherapeutics, Inc.","relationship":"other board seat held by new director"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine single-director board appointment with no change in strategy, leadership, or capital structure. Mildly notable that the new director is a professional investor joining the Audit Committee ahead of a potential seralutinib FDA decision, but this is standard corporate governance news."},"tickerRelevance":{"others":[],"primary":"GOSS"},"globalImportance":14,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine-board-appointment","sectorWeight":"clinical-stage biotech with FDA catalyst pending","governanceRoutine":true,"auditCommitteeRole":"minor positive signal on governance"}},"event_type":"board_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Gossamer Bio appointed Greg Ciongoli to its Board of Directors, effective September 16, 2026, with a seat on the Audit Committee.\n\nCiongoli is founder and managing partner of Boston-based Adiumentum Capital Management and previously a partner at the Baupost Group; he also sits on the boards of REGENXBIO, Zymeworks, and Atara Biotherapeutics.\n\nCEO Faheem Hasnain framed the addition as bringing investment and value-creation perspective as Gossamer advances seralutinib toward a potential FDA approval in pulmonary arterial hypertension and PH-ILD.","key_figures":{},"named_entities":{"people":[{"name":"Greg Ciongoli","role":"Newly appointed Director and Audit Committee member, Gossamer Bio"},{"name":"Faheem Hasnain","role":"Chairman, Co-Founder and CEO, Gossamer Bio"},{"name":"Bryan Giraudo","role":"CFO & COO, Gossamer Bio (investor/media contact)"}],"products":["seralutinib"],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS","relationship":"filer"},{"name":"Adiumentum Capital Management","relationship":"new director's current firm (founder & managing partner)"},{"name":"Baupost Group","relationship":"new director's prior employer (partner)"},{"name":"REGENXBIO Inc.","relationship":"other board seat held by new director"},{"name":"Zymeworks, Inc.","relationship":"other board seat held by new director"},{"name":"Atara Biotherapeutics, Inc.","relationship":"other board seat held by new director"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-16T20:01:21.182Z","global_importance":14,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine-board-appointment","sectorWeight":"clinical-stage biotech with FDA catalyst pending","governanceRoutine":true,"auditCommitteeRole":"minor positive signal on governance"}},"durationMs":20987,"modelName":"glm-5.3-flash"}}